Stockscreener 앱 받기
2.23
0.45%
-0.01
Gt Biopharma Inc 주식(GTBP)의 최신 뉴스
GT Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GT Biopharma appoints new board member By Investing.com - Investing.com Nigeria
GT Biopharma (GTBP) Welcomes New Board Member Andrew Ritter | GTBP Stock News - GuruFocus
GT Biopharma Appoints New Member to its Board of Directors - The Manila Times
GT Biopharma appoints new board member - Investing.com
GT Biopharma Strengthens Board with Biotech Exit Expert Andrew Ritter: 3 Successful Company Sales - Stock Titan
GT Biopharma (GTBP) Appoints Hilary Kramer to Board of Directors - GuruFocus
GT Biopharma adds Hilary Kramer to Board of Directors By Investing.com - Investing.com Canada
GT Biopharma Appoints New Member To Its Board Of Directors - marketscreener.com
GT Biopharma adds Hilary Kramer to Board of Directors - Investing.com
$12B Portfolio Expert Hilary Kramer to Guide NK Cell Pioneer GT Biopharma's Clinical Expansion - Stock Titan
GT Biopharma (GTBP) Projected to Post Earnings on Wednesday - Defense World
GT Biopharma Board Restructures with New Appointments - TipRanks
GT Biopharma announces private placement deal - Investing.com
GT Biopharma Secures $5.45M in Private Placement - TipRanks
Nanobodies Market to Reach US$ 2.27 Billion by 2031: Growth - openPR.com
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
GT Biopharma (NASDAQ:GTBP) Trading Down 1.7% – Time to Sell? - The AM Reporter
Nanobodies Market Gains Momentum with Advancements in Immunotherapy | Ablynx, Sanofi, Merck - openPR.com
GT Biopharma Appoints Michael Breen as New CEO - TipRanks
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
GT Biopharma, Inc. Announces Corporate Update Conference Call with CEO Dr. Kathleen Clarence-Smith, CMO Dr. Raymond Urbanski and Chairman Anthony Cataldo - ACCESS Newswire
Xeris Biopharma Holdings Inc (XERS) stock analysis: A simple moving average approach - uspostnews.com
GT Biopharma Announces $7.1 Million Convertible Debt Financing - ACCESS Newswire
GT Biopharma Announces Completion of $5.6 Million Bridge Financing - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Nanobodies Market Growth, Opportunities and Future Scope 2025-2032 | Merck KGaA, Sanofi, AlpalifeB Inc - newstrail.com
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve
GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak - MSN
GT Biopharma Issues Warrant to Cytovance for Services Rendered - Investing.com Australia
GT Biopharma Issues Warrant to Cytovance for Services Rendered By Investing.com - Investing.com Canada
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - Yahoo Finance
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
North American Morning Briefing : Stock Futures -2- - MarketScreener
GT Biopharma (GTBP) Projected to Post Quarterly Earnings on Tuesday - Defense World
Nanobodies Market Detailed In New Research Report 2025 | Sanofi, - openPR
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential - MarketBeat
The Goodyear Tire & Rubber Company (GT): A Bull Case Theory - Yahoo Finance
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit - GlobeNewswire
Can GT Biopharma's TriKE® Technology Transform Blood Cancer Treatment? Phase 1 Trial Updates Coming in 2025 - StockTitan
GT Biopharma Launches Shareholder Communications Initiative - ACCESS Newswire
Roth Capital Has Weak Forecast for GT Biopharma Q1 Earnings - Defense World
Analysts Issue Forecasts for GT Biopharma FY2029 Earnings - Defense World
GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial - ACCESS Newswire
1.54%
7.58%
자본화:
|
볼륨(24시간):